| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MER; RP38; c-Eyk; c-mer; Tyro12 |
| Entrez GeneID | 10461 |
| clone | 3D11G8 |
| WB Predicted band size | 140-180 kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MERTK (AA:extra(21-220)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4条关于MERTK抗体的参考文献及其摘要概括：
1. **文献名称**：*Targeting MERTK Enhances Immune Checkpoint Blockade Efficacy in Preclinical Models*
**作者**：Christoph J. Rader 等
**摘要**：研究开发了一种人源化抗MERTK单克隆抗体，通过阻断MERTK介导的肿瘤微环境中凋亡细胞吞噬作用，增强T细胞抗肿瘤免疫反应，并与PD-1抑制剂联用显著抑制小鼠肿瘤生长。
2. **文献名称**：*MERTK Inhibition Reprograms Macrophages to Promote Phagocytosis and Antitumor Immunity*
**作者**：Douglas K. Graham 等
**摘要**：该研究利用特异性MERTK抗体阻断MERTK信号通路，逆转肿瘤相关巨噬细胞的免疫抑制表型，促进吞噬肿瘤细胞并激活适应性免疫，为实体瘤治疗提供新策略。
3. **文献名称**：*Therapeutic Anti-MERTK Antibodies for the Treatment of Autoimmune Disease*
**作者**：Gregory Lemke 等
**摘要**：通过动物模型证明，抗MERTK抗体可调节巨噬细胞功能，减少自身免疫性炎症反应(如类风湿性关节炎)，提出MERTK抗体在自身免疫疾病中的治疗潜力。
4. **文献名称**：*MERTK as a Novel Therapeutic Target in Cancer Immunotherapy*
**作者**：Jennifer A. Kearney 等
**摘要**：综述总结了MERTK在肿瘤免疫逃逸中的作用，重点讨论抗MERTK抗体的机制(如阻断Gas6配体结合)及临床前/临床试验进展，强调其联合其他疗法的前景。
以上文献聚焦于MERTK抗体在肿瘤免疫、巨噬细胞调控及自身免疫疾病中的应用，涵盖机制探索与治疗开发。
MERTK (MER Proto-Oncogene, Tyrosine Kinase) is a receptor tyrosine kinase belonging to the TAM family (TYRO3. AXL, MERTK), which regulates critical cellular processes such as proliferation, survival, migration, and immune modulation. It is activated by binding to ligands like Gas6 and Protein S, initiating downstream signaling pathways. MERTK is widely expressed in epithelial, immune, and neural cells, playing roles in tissue homeostasis, phagocytosis, and resolution of inflammation. Dysregulation of MERTK is implicated in pathologies, including cancer, autoimmune diseases, and retinal disorders.
In cancer, MERTK overexpression promotes tumor survival, immune evasion, and therapy resistance by suppressing anti-tumor immunity. This has spurred interest in developing MERTK-targeted therapies, such as monoclonal antibodies. MERTK antibodies block ligand binding or receptor activation, inhibiting oncogenic signaling and enhancing immune recognition. Preclinical studies show efficacy in solid tumors (e.g., melanoma, lung cancer) and hematologic malignancies.
MERTK antibodies also hold promise in treating age-related macular degeneration (AMD) by modulating retinal pigment epithelium phagocytosis. Additionally, they are explored in autoimmune contexts to counteract excessive TAM-mediated immunosuppression. Challenges include optimizing selectivity to avoid off-target effects and overcoming resistance mechanisms. Several MERTK-targeting antibodies are in early-stage clinical trials, highlighting their therapeutic potential across diverse diseases.
×
